Dementia Associated With Alzheimer’s Disease – Drugs In Development, 2024
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Dementia Associated With Alzheimer’s Disease – Drugs In Development, 2024 report and make more profitable business decisions.
Alzheimer’s disease (AD) is the most common cause of dementia. AD is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and changes in behavior and thinking skills that interfere with daily functioning. Early symptoms may include mild forgetfulness, difficulty recalling recent events or information, and trouble with problem-solving or complex tasks.
One of the hallmark features of AD is the impairment of memory, particularly short-term memory. Individuals may have trouble remembering recent conversations, names, or important dates. As the disease progresses, individuals may experience changes in behavior, mood swings, confusion, disorientation, difficulty in following conversations, and problems with language (aphasia). They may also withdraw from social activities and exhibit changes in personality. Alzheimer’s disease is associated with the accumulation of abnormal protein deposits in the brain, including beta-amyloid plaques and tau tangles, which disrupt communication between brain cells, leading to their degeneration and death.
The Dementia Associated With Alzheimer’s Disease drugs in development market research report provide comprehensive information on the therapeutics under development for Dementia Associated With Alzheimer’s Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dementia Associated With Alzheimer’s Disease and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
Quick View – Dementia Associated With Alzheimer's Disease | Key Targets |
|
|
Key Mechanisms of Action |
|
||
Key Routes of Administration |
|
||
Key Molecule Types |
|
||
Major Companies |
|
Scope
- Therapeutics in Development: Covering 54 molecules, with 51 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Dementia Associated With Alzheimer’s Disease therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Dementia Associated With Alzheimer’s Disease pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Dementia Associated With Alzheimer’s Disease treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Actinogen Medical LtdAcumen Pharmaceuticals Inc
ADEL Inc
AlphaCognition Inc
Alzamend Neuro Inc
AULBIO Co Ltd
Avanir Pharmaceuticals Inc
Avineuro Pharmaceuticals Inc
Axsome Therapeutics Inc
Biogen Inc
Cassava Sciences Inc
Cellivery Therapeutics Inc
Cellular Biomedicine Group Ltd
Celosia Therapeutics Pty Ltd
Center for Drug Research and Development
Corepharm Bio Co Ltd
CuraSen Therapeutics Inc
Cytora Ltd
Dadang & BIO Co Ltd
Digmbio
Echo Pharmaceuticals BV
Eisai Co Ltd
Ensol Biosciences Inc
G2GBIO Inc
IGC Pharma Inc
Johnson & Johnson
Korea Institute of Science and Technology
Korea Pharma Co Ltd
Lachesis Biosciences Ltd
LP Pharmaceutical (Xiamen) Co Ltd
Luye Pharma Group Ltd
MediPost Co Ltd
Mirae Cell Bio Co Ltd
Neurim Pharmaceuticals Ltd
Novo Nordisk AS
Onodera Medical Co Ltd
Otsuka Pharmaceutical Co Ltd
ProNeurogen Inc
RAFT Pharmaceuticals LLC
RegenInnopharm Inc
Sage Therapeutics Inc
SinoMab Bioscience Ltd
Skin2Neuron Pty Ltd
Stemedica International S.A.
Suven Life Sciences Ltd
Teikoku Pharma USA Inc
Vanderbilt University
Vivoryon Therapeutics NV
Whan In Pharm Co Ltd